Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) and VistaGen Therapeutics (NASDAQ:VTGN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.
Institutional & Insider Ownership
78.4% of VistaGen Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of current ratings and recommmendations for Zealand Pharma A/S and VistaGen Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Zealand Pharma A/S | 0 | 9 | 1 | 1 | 2.27 |
| VistaGen Therapeutics | 1 | 4 | 0 | 0 | 1.80 |
Profitability
This table compares Zealand Pharma A/S and VistaGen Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Zealand Pharma A/S | 58.86% | 17.56% | 16.17% |
| VistaGen Therapeutics | -2,702.64% | -152.59% | -117.45% |
Risk & Volatility
Zealand Pharma A/S has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500. Comparatively, VistaGen Therapeutics has a beta of 0.39, meaning that its share price is 61% less volatile than the S&P 500.
Valuation and Earnings
This table compares Zealand Pharma A/S and VistaGen Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Zealand Pharma A/S | $1.40 billion | 2.24 | $977.29 million | $6.03 | 7.24 |
| VistaGen Therapeutics | $1.27 million | 10.76 | -$69.68 million | ($1.66) | -0.19 |
Zealand Pharma A/S has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Zealand Pharma A/S beats VistaGen Therapeutics on 11 of the 15 factors compared between the two stocks.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
About VistaGen Therapeutics
Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
